Company intelligence / Profile preview

Nexstim

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Nexstim’s NBS 5/6 systems are CE-marked and FDA-cleared devices used globally in over 140 hospitals/research centers. Clinical studies have shown meaningful results in pre-surgical mapping accuracy as well as symptom relief for depression and chronic pain. The company continues to expand its commercial footprint with new system orders internationally.

Therapeutic areas: PsychiatryNeurology
Modalities: DeviceNon-pharmacological therapy
Industry: Medical Imaging

Partnerships

Sinaptica Therapeutics Inc.: Collaboration on precision neuromodulation device development/manufacturing based on NBS platform.Brainlab AG: Development/distribution partnership for non-invasive brain mapping solutions.Collaborations with Medtronic and Stryker neuronavigational systems integration.

Beyond the preview

Go deeper on Nexstim.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nexstim.

Explore the full profile